Global Age-Related Macular Degeneration (AMD) Market Size, Share, Development, Growth and Demand Forecast to 2022 – Industry Insights by Type (Dry AMD, and Wet AMD), by Drug (Lucentis, Eylea, Visudyne, Avastin and Others)

Chapter 1. Research Scope and Methodology  

1.1 Market Definition

1.2 Market Scope    

1.2.1 Global AMD market breakdown by type

1.2.2 Global AMD market breakdown by drug

1.2.3 Global AMD market breakdown by geography

1.3 Research Methodology and Sources    

Chapter 2. Executive Summary

2.1 Key Findings      

2.2 Research Summary

Chapter 3. Market Outlook

3.1 Introduction

3.1.1 Diagnosis of AMD

3.1.2 Stages of AMD

3.1.3 Treatment of AMD

3.1.4 Various drugs for the treatment of AMD

3.1.4.1 Lucentis

3.1.4.2 Eylea

3.1.4.3 Avastin

3.1.4.4 Visudyne      

3.2 Trends in the Market     

3.2.1 Increasing awareness of AMD

3.3 Factors Driving Growth of the Market and its Impact on Market Forecast

3.3.1 Growing geriatric population  

3.3.2 Increasing prevalence of AMD

3.3.3 Increasing prevalence of lifestyle associated diseases

3.3.4 Increasing pipeline drugs for AMD    

3.3.5 Increasing healthcare cost

3.3.6 Impact analysis of drivers on market forecast

3.4 Factors Hindering the Growth of the Market and its Impact on Market Forecast    

3.4.1 Increase in off label use

3.4.2 Stringent regulatory requirements    

3.4.3 Impact analysis of restraints on market forecast   

Chapter 4. Drug Approval Process in the U.S. and EU

4.1 Drug approval process in the U.S.

4.2 Drug approval process in the EU

Chapter 5. Global Age-related Macular Degeneration Market Size and Forecast (2012 – 2022)

5.1 Global AMD Market, by Type    

5.2 Global AMD Market, by Drug    

5.3 Global AMD Market, by Region

Chapter 6. Global Age-related Macular Degeneration Market, by Type

6.1 Dry AMD Market

6.2 Wet AMD Market

Chapter 7. Global Age-related Macular Degeneration Market, by Geography     

7.1 North America AMD Market

7.1.1 North America AMD market, by type

7.1.2 North America AMD market, by country

7.2 Europe AMD Market

7.2.1 Europe AMD market, by type

7.2.2 Europe AMD market, by country

7.3 Asia-Pacific AMD Market

7.3.1 Asia-Pacific AMD market, by type

7.3.2 Asia-Pacific AMD market, by country

7.4 Rest of the World (RoW) AMD Market

7.4.1 RoW AMD market, by type

Chapter 8. Competitive Positioning Analysis

8.1 Porter’s Five Forces of Competitive Position Analysis

8.1.1 Bargaining power of buyers  

8.1.2 Bargaining power of suppliers

8.1.3 Threat of new entrants

8.1.4 Intensity of rivalry

8.1.5 Threat of substitutes  

8.2 Pipeline Analysis of AMD drugs

Chapter 9. Company Profiles and Strategic Developments

9.1 Key Company Profiles

9.1.1 Novartis AG

9.1.1.1 Business overview

9.1.1.2 Product and service offerings

9.1.2 F. Hoffmann-La Roche Ltd

9.1.2.1 Business overview

9.1.2.2 Product and service offerings

9.1.3 Bayer AG.

9.1.3.1 Business overview

9.1.3.2 Product and service offerings

9.1.4 Regeneron Pharmaceutical, Inc.

9.1.4.1 Business overview

9.1.4.2 Product and service offerings

9.1.5 Acucela

9.1.5.1 Business overview

9.1.5.2 Product and service offerings

9.1.6 Ophthotech Corporation

9.1.6.1 Business overview

9.1.6.2 Product and service offerings

9.1.7 Neurotech Pharmaceuticals, Inc.

9.1.7.1 Business overview

9.1.7.2 Product and service offerings

9.1.8 GlaxoSmithKline plc

9.1.8.1 Business overview

9.1.8.2 Product and service offerings

9.1.9 StemCells Inc.

9.1.9.1 Business overview

9.1.9.2 Product and service offerings

9.1.10 Alimera Sciences, Inc.

9.1.10.1 Business overview

9.1.10.2 Product and service offerings

9.2 Strategic Developments in the AMD Market

9.2.1 Collaborations/ partnerships  

9.2.2 Product approval/launch

9.2.3 Merger and acquisition

9.2.4 Other developments   

Chapter 10. Appendix

10.1 List of Abbreviations    

 

LIST OF TABLES

TABLE 1 SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION         

TABLE 2 GLOBAL AMD MARKET SNAPSHOT

TABLE 3 SOME OF THE PIPELINE DRUGS OF AMD IN MAJOR COMPANIES

TABLE 4 HEALTHCARE EXPENDITURE AS % OF GDP        

TABLE 5 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 6 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 7 GLOBAL AMD MARKET, BY TYPE, $M (2012 – 2015)

TABLE 8 GLOBAL AMD MARKET, BY TYPE, $M (2016 – 2022)

TABLE 9 GLOBAL AMD MARKET, BY DRUG, $M (2012 – 2015)

TABLE 10 GLOBAL AMD MARKET, BY DRUG, $M (2016 – 2022)

TABLE 11 GLOBAL AMD MARKET, BY REGION, $M (2012 – 2015)

TABLE 12 GLOBAL AMD MARKET, BY REGION, $M (2016 – 2022)

TABLE 13 GLOBAL DRY AMD MARKET, BY REGION, $M (2012 – 2015)

TABLE 14 GLOBAL DRY AMD MARKET, BY REGION, $M (2016 – 2022)

TABLE 15 GLOBAL WET AMD MARKET, BY REGION, $M (2012 – 2015)

TABLE 16 GLOBAL WET AMD MARKET, BY REGION, $M (2016 – 2022)

TABLE 17 NORTH AMERICA AMD MARKET, BY TYPE, $M (2012 – 2015)

TABLE 18 NORTH AMERICA AMD MARKET, BY TYPE, $M (2016 – 2022)

TABLE 19 NORTH AMERICA AMD MARKET, BY COUNTRY, $M (2012 – 2015)

TABLE 20 NORTH AMERICA AMD MARKET, BY COUNTRY, $M (2016 – 2022)

TABLE 21 EUROPE AMD MARKET, BY TYPE, $M (2012 – 2015)

TABLE 22 EUROPE AMD MARKET, BY TYPE, $M (2016 – 2022)

TABLE 23 EUROPE AMD MARKET, BY COUNTRY, $M (2012 – 2015)

TABLE 24 EUROPE AMD MARKET, BY COUNTRY, $M (2016 – 2022)        

TABLE 25 ASIA-PACIFIC AMD MARKET, BY TYPE, $M (2012 – 2015)

TABLE 26 ASIA-PACIFIC AMD MARKET, BY TYPE, $M (2016 – 2022)

TABLE 27 ASIA-PACIFIC AMD MARKET, BY COUNTRY, $M (2012 – 2015)

TABLE 28 ASIA-PACIFIC AMD MARKET, BY COUNTRY, $M (2016 – 2022)

TABLE 29 ROW AMD MARKET, BY TYPE, $M (2012 – 2015)

TABLE 30 ROW AMD MARKET, BY TYPE, $M (2016 – 2022)

TABLE 31 NOVARTIS AG – KEY FACTS

TABLE 32 F. HOFFMANN-LA ROCHE LTD – KEY FACTS

TABLE 33 BAYER AG – KEY FACTS

TABLE 34 REGENERON PHARMECEUTICALS, INC. – KEY FACTS

TABLE 35 ACUCELA– KEY FACTS

TABLE 36 OPHTHOTECH CORPORATION– KEY FACTS

TABLE 37 NEUROTECH PHARMACEUTICALS, INC.– KEY FACTS

TABLE 38 GLAXOSMITHKLINE PLC – KEY FACTS

TABLE 39 STEMCELLS INC.– KEY FACTS

TABLE 40 ALIMERA SCIENCES, INC. KEY FACT

LIST OF FIGURES

FIG 1 MARKET SCOPE FOR GLOBAL AMD MARKET

FIG 2 RESEARCH METHODOLOGY FOR GLOBAL AMD MARKET

FIG 3 ANATOMICAL STRUCTURE OF AN EYE

FIG 4 CROSS SECTION OF A MACULA

FIG 5 AMSLER GRID TEST

FIG 6 OPTICAL COHERENCE TOMOGRAPHY OF AN EYE

FIG 7 INNOVATION OF WET AMD TREATMENT

FIG 8 AGING POPULATION AS A PERCENTAGE OF TOTAL POPULATION, IN MAJOR COUNTRIES

FIG 9 PREVALENCE OF OVERWEIGHT MEN AGED 30 AND ABOVE, IN % (2005 AND 2015)

FIG 10 PREVALENCE OF OVERWEIGHT WOMEN AGED 30 AND ABOVE, IN % (2005 AND 2015)

FIG 11 BASIC DRUG DEVELOPMENT PROCEDURE

FIG 12 GLOBAL AMD MARKET SIZE, $M (2012 – 2022)

FIG 13 GLOBAL AMD MARKET SIZE, BY TYPE, $M (2012 – 2022) 

FIG 14 GLOBAL AMD MARKET SIZE, BY DRUG, $M (2012 – 2022)

FIG 15 GLOBAL AMD MARKET SHARE, BY DRUG (2015 AND 2022)

FIG 16 GLOBAL AMD MARKET SIZE, BY REGION, $M (2012 – 2022)

FIG 17 GLOBAL AMD MARKET SHARE, BY REGION (2015 AND 2022)

FIG 18 GLOBAL DRY AMD MARKET SIZE, BY REGION, $M (2012 – 2022)

FIG 19 GLOBAL WET AMD MARKET SIZE, BY REGION, $M (2012 – 2022)

FIG 20 GLOBAL AMD MARKET SIZE, BY GEOGRAPHY (2022)

FIG 21 NORTH AMERICA AMD MARKET SIZE, BY TYPE, $M (2012 – 2022)

FIG 22 NORTH AMERICA AMD MARKET SIZE, BY COUNTRY, $M (2012 – 2022)

FIG 23 EUROPE AMD MARKET SIZE, BY TYPE, $M (2012 – 2022) 

FIG 24 EUROPE AMD MARKET SIZE, BY COUNTRY, $M (2012 – 2022)

FIG 25 ASIA-PACIFIC AMD MARKET SIZE, BY TYPE, $M (2012 – 2022)

FIG 26 ASIA-PACIFIC AMD MARKET SIZE, BY COUNTRY, $M (2012 – 2022)

FIG 27 ROW AMD MARKET SIZE, BY TYPE, $M (2012 – 2022)

FIG 28 PORTER’S FIVE FORCES OF COMPETITIVE POSITION ANALYSIS

FIG 29 PIPELINE ANALYSIS OF AMD DRUGS (2015)